

Inhalation Sciences Q3 - Continuing its journey towards profitability

Redeye provides an update in relation to ISAB's Q3 2023 report. Revenues during the quarter amounted to SEK3.4m (SEK1.8m), and EBIT came in at SEK-1.0m (SEK-3.5m). Revenues came in lower than anticipated; however, ISAB continues to keep its costs low. Moreover, we note that the order flow after the reporting period has been solid, arguing the coming quarters will be interesting for the company. We make some adjustments to our OPEX estimates and increase our WACC. However, the changes do not render in an updated fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Inhalation Sciences Q3 - Continuing its journey towards profitability